All In Biotech

NDA 209510 · Lxo Ireland

Barhemsys

Amisulpride · Intravenous · Dopamine-2 Receptor Antagonist

Novel

Last checked: Nov 20, 2026Latest source record: Sep 14, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2020

Feb 26, 2020

Approved uses

1

Original approval plus efficacy supplements

Registered trials

75

14 Phase 3, 3 recruiting

FAERS reports

6,123

6,004 serious, 796 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 17, 2026.

BARHEMSYS ® is indicated in adults for: prevention of postoperative nausea and vomiting (PONV), either alone or in combination with an antiemetic of a different class. treatment of PONV in patients who have received antiemetic prophylaxis with an agent of a different class or have not received prophylaxis. BARHEMSYS is a dopamine-2 (D 2 ) antagonist indicated in adults for: Prevention of postoperative nausea and vomiting (PONV), either alone or in combination with an antiemetic of a different class. ( 1 ) Treatment of PONV in patients who have received antiemetic prophylaxis with an agent of a different class or have not received prophylaxis. ( 1 )

Mechanism: Amisulpride is a selective dopamine-2 (D 2 ) and dopamine-3 (D 3 ) receptor antagonist. D 2 receptors are located in the chemoreceptor trigger zone (CTZ) and respond to the dopamine released from the nerve endings. Activation of CTZ relays stimuli to the vomiting center which is involved in emesis. Studies in multiple species indicate that D 3 receptors in the area postrema also play a role in emesis. Studies conducted in ferrets have shown that amisulpride inhibits emesis caused by apomorphine, with an estimated ED 50 of less than 1 mcg/kg, subcutaneously; and inhibits cisplatin-induced...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 26, 2020 Original approval · Type 1 - New Molecular Entity NovelLabelLetterReview
2 products under this application
  • BARHEMSYS · AMISULPRIDE 10MG/4ML (2.5MG/ML) · SOLUTION, INTRAVENOUS · Prescription
  • BARHEMSYS · AMISULPRIDE 5MG/2ML (2.5MG/ML) · SOLUTION, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Amisulpride" as an intervention, any sponsor and status, largest first.

All 75 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective872
  • drug interaction483
  • weight increased446
  • toxicity to various agents416
  • neutropenia408
  • schizophrenia339
  • off label use333
  • leukopenia316
  • akathisia307
  • extrapyramidal disorder302
  • electrocardiogram qt prolonged283
  • suicide attempt282

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200432
200549
200665
200779
200875
2009111
2010162
2011189
2012194
2013229
2014224
2015223
2016216
2017287
2018376
2019451
2020379
2021397
2022481
2023469
2024635
2025467
2026331

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 363 on PubMed

Sponsor: Lxo Ireland

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.